Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B), while Vanguard Dividend Appreciation Index Fund ETF trades at $246.1. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals.
| BMY | VIG | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $245.79 |
52-Week Low | $42.60 | $208.67 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
VIG trades at $245.92, up 0.05% on the day, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on dividend growth stocks like Broadcom, offering a 1.5% yield with a 20-year dividend growth streak. Recent news highlights its role in retirement income strategies amid Social Security adjustments.
Outlook remains positive for long-term investors seeking stable dividend growth, though high RSI levels suggest near-term consolidation risks. Competition with higher-yield ETFs and market volatility pose challenges, but institutional interest and consistent methodology support resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
